Vir Biotechnology (VIR) to Release Quarterly Earnings on Monday

Vir Biotechnology (NASDAQ:VIR) will likely be announcing its Q4 2025 results after the market closes on Monday, February 23rd. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $19.9050 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, February 23, 2026 at 5:30 PM ET.

Vir Biotechnology Trading Down 3.3%

Shares of VIR stock opened at $7.56 on Friday. The company has a market capitalization of $1.05 billion, a price-to-earnings ratio of -2.09 and a beta of 1.69. Vir Biotechnology has a 1-year low of $4.16 and a 1-year high of $9.93. The stock’s fifty day simple moving average is $6.73 and its 200-day simple moving average is $5.92.

Insider Buying and Selling

In other news, Director Vicki L. Sato sold 22,000 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $7.71, for a total transaction of $169,620.00. Following the completion of the transaction, the director owned 1,144,391 shares of the company’s stock, valued at approximately $8,823,254.61. This represents a 1.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Endurance (Cayman) Ltd Svf sold 191,854 shares of Vir Biotechnology stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $5.98, for a total value of $1,147,286.92. Following the sale, the insider directly owned 13,728,924 shares in the company, valued at approximately $82,098,965.52. This trade represents a 1.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 912,589 shares of company stock worth $5,711,308 in the last ninety days. Insiders own 16.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC boosted its holdings in shares of Vir Biotechnology by 2,088.4% in the 1st quarter. AQR Capital Management LLC now owns 268,297 shares of the company’s stock worth $1,739,000 after acquiring an additional 256,037 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Vir Biotechnology during the 1st quarter valued at $359,000. Goldman Sachs Group Inc. boosted its stake in Vir Biotechnology by 43.6% in the first quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company’s stock worth $4,813,000 after purchasing an additional 225,544 shares in the last quarter. Woodline Partners LP boosted its stake in Vir Biotechnology by 245.6% in the first quarter. Woodline Partners LP now owns 466,737 shares of the company’s stock worth $3,024,000 after purchasing an additional 331,701 shares in the last quarter. Finally, Focus Partners Wealth grew its holdings in shares of Vir Biotechnology by 15.3% during the first quarter. Focus Partners Wealth now owns 19,317 shares of the company’s stock worth $125,000 after purchasing an additional 2,566 shares during the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Analyst Upgrades and Downgrades

VIR has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Monday, December 22nd. Needham & Company LLC reissued a “buy” rating and issued a $14.00 price objective on shares of Vir Biotechnology in a research note on Monday, February 9th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Vir Biotechnology in a research report on Tuesday, December 30th. Finally, Barclays set a $26.00 price target on Vir Biotechnology in a report on Tuesday. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $16.29.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.